People with Down Syndrome (DS) are at high risk for Alzheimer’s disease (AD) because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD.
Advancing knowledge of human development, developmental disabilities, and neurodegenerative diseases.